drugset
drugset / Trial / NCT05170763

Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

NCT05170763 ↗

Phase 1 Completed 60 enrolled Anhui Palo Alto Pharmaceuticals, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult

Timeline

Start
2021-11-10
Primary completion
2022-01-05
Completion
2022-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject PA9159 Small molecule 10 ug Intranasal
Subject PA9159 Small molecule 20 ug Intranasal
Subject PA9159 Small molecule 40 ug Intranasal
Subject PA9159 Small molecule 80 ug Intranasal

Indications

allergic rhinitis